Ionis Pharmaceuticals Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.0% | -4.6% | +44.9% | +101.8% | +21.2% | -26.1% | +9.3% | -3.0% | +18.0% | +0.5% | +17.3% | |
| – | +0.0% | -4.7% | +46.4% | +89.0% | +23.2% | -21.7% | +10.1% | -6.1% | +19.9% | -0.8% | +14.1% | |
| – | +6.9% | -14.6% | +53.7% | +103.8% | +20.0% | -24.3% | +11.8% | -86.9% | +44.4% | -39.4% | +53.8% | |
| – | -0.8% | -17.0% | +53.2% | +103.8% | +20.0% | -24.3% | +11.8% | -5.6% | +16.7% | -1.4% | +16.5% | |
| – | +191.0% | +851.4% | -41.7% | -79.7% | +393.8% | +20.6% | -18.4% | -58.8% | +282.9% | -5.7% | -28.4% | |
| – | +9.7% | +8.6% | +33.3% | -14.0% | +111.8% | +20.8% | +12.9% | -11.2% | -66.2% | +68.1% | -19.7% | |
| – | +1.4% | +2.9% | +31.3% | +8.4% | +16.3% | +17.8% | -1.7% | -58.3% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -2.8% | +5.4% | +8.0% | +9.2% | +6.8% | +8.8% | +3.8% | – | – | – | – | |
| – | +8.2% | +7.6% | +11.1% | +63.9% | +4.6% | -0.1% | +18.9% | +6.6% | +32.8% | -7.2% | +25.6% | |
| – | +29.1% | -10.1% | +68.0% | +24.7% | -2.6% | +6.2% | -16.9% | +29.3% | +43.8% | -31.0% | +152.7% | |
| – | +213.3% | -86.9% | +36.8% | +748.2% | -85.3% | +14,369.9% | -98.8% | +113.7% | +605.5% | -82.5% | +4,783.6% | |
| – | +57.7% | -25.5% | +17.8% | +15.2% | -43.9% | +7.0% | -30.8% | +50.5% | +45.2% | +65.1% | -34.6% | |
| – | -12.6% | +25.9% | +18.4% | +5.9% | +22.6% | -33.0% | +136.8% | -3.1% | +4.0% | +1.3% | +8.2% | |
| – | -22.1% | -50.4% | +320.5% | +183.5% | +41.9% | -50.0% | -8.4% | -25.8% | -32.5% | +52.2% | -16.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.7% | +1.0% | +4.3% | +6.3% | +6.6% | -2.3% | +1.0% | +0.6% | +0.9% | +4.4% | +7.0% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.